Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
— LEGAOfficial title:
"A Prospective, Cross-over Randomized Trial to Assess the Efficacy and Safety of Mechanical Percussor "LEGA" Compared With Conventional Chest Physiotherapy in Adults With Chronic Bronchiectasis or Chronic Obstructive Pulmonary Disease (COPD
Verified date | December 2012 |
Source | Penang Hospital, Malaysia |
Contact | n/a |
Is FDA regulated | No |
Health authority | Malaysia: Ministry of Health |
Study type | Interventional |
A Malaysian company by name Formedic Technologies SDN BHD has devised a hand held machine
which is supposed to mimic the chest percussion performed by professional physiotherapist to
mobilize sputum through the respiratory passage.
The aim of this study is to compare the effectiveness and safety of this mechanical
percussion device in the treatment of airway clearance with conventional chest physiotherapy
carried out by qualified physiotherapists in patients suffering from bronchiectasis or
Chronic obstructive Pulmonary disease (COPD).
Status | Completed |
Enrollment | 20 |
Est. completion date | June 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Adult patients > 18 years of age 2. Chronic sputum expectoration-(producing >30ml/day of sputum at baseline) 3. Clinical diagnosis of bronchiectasis or COPD 4. Not carrying out regular chest physiotherapy (for the purposes of this study this will be defined as less than two occasions per week) 5. Clinically stable disease (defined as no requirement for antibiotics in the 4 weeks preceding study entry). 6. FEV1 of > 35% of the predicted value in COPD patients Exclusion Criteria: 1. Primary diagnosis of asthma; 2. Active sarcoidosis 3. Active Pulmonary tuberculosis. 4. History of brittle bones, 5. History of broken ribs in the past one year. 6. History of severe osteoporosis 7. Bleeding from the lungs or haemoptysis 8. Experiencing intense pain in the thoracic region 9. Clinical suspicion of increased intracranial pressure. 10. Have head or neck injuries 11. Have collapsed lungs or a damaged chest wall; 12. Recent myocardial infarction, unstable angina and stroke (Within 6 months prior to enrollment) 13. Have a pulmonary embolism or lung abscess; 14. Have an active hemorrhage 15. Have injuries to the spine 16. Have open wounds or burns in the thoracic region 17. Have had recent surgery (Within six months prior to enrollment.) 18. Any systemic steroids within 4/52 prior to enrollment 19. Any antibiotics within 4/52 prior to enrollment |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Malaysia | Penang hospital | George Town | Penang |
Lead Sponsor | Collaborator |
---|---|
Penang Hospital, Malaysia |
Malaysia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparing the 'wet weight' and 'dry weight' of the sputum expectorated during 20 minutes of the two procedures. | The patients will be instructed to cough out the sputum into a preweighed container during the 15 minutes of the procedure(Manual or mechanical percussion)and 5 minutes after the procedure.Container will be weighed to get the wet weight of the sputum then will be dried in a laboratory oven at 60degree c for 48 hours and weighed again to get the dry weight of the sputum | 6 days | No |
Secondary | Change in FEV1 and FVC before and after the two methods of therapy | Any changes in the lung function will be measured as - FEV1 (%predicted) and FVC (%predicted) | 15 minutes after completion of the procedure compared to baseline | No |
Secondary | Changes in pulse, blood pressure and respiratory rate | Monitoring of Pulse, blood pressure, respiratory rate, skin colour and patients reaction to treatment. | 15 minutes after completion of treatment compared to baseline | Yes |
Secondary | Patient preference | Patients will be participating in the study for 6 days. On the 6th day after completion of treatment they will be required to answer a simple questionnaire to find out if they prefer one procedure over the other and why. | After completing 6 days of participation in the study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |